Paul M. Bunch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul M. Bunch has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Hillary R. Kelly
From the Department of Radiology (S.M., M.E.C., A.F.J., K.L.R., Y.-S.C., M.P.), Massachusetts Eye and Ear, Radiation Oncology (N.T.M.), Massachusetts General Hospital, Otolaryngology-Head and Neck Surgery (G.W.R.), Massachusetts Eye and Ear Infirmary and Radiology (H.R.K.), Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
7 shared publications - Jeffrey R. Sachs
Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC
6 shared publications Reese W. Randle
Department of Surgery, Wake Forest University School of Medicine, Winston-Salem, NC
6 shared publications- Courtney M. Tomblinson
From the Department of Diagnostic Radiology, University of California Los Angeles, 757 Westwood Plaza, Ste 1638, Los Angeles, CA 90095 (J.E.C.); Department of Radiology, University of California San Diego, San Diego, Calif (M.H.); Department of Diagnostic Radiology, University of Chicago Medicine, Chicago, Ill (J.H.M.); and Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tenn (C.M.T.).
5 shared publications Leon Lenchik
Associate Dean for Faculty Mentoring; Vice Chair of Faculty Development; Division Chief of Musculoskeletal Imaging, Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
5 shared publications- Christopher M. Lack
Department of Radiology, Atrium Health Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA
4 shared publications
Latest Publications
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (7) , e250084
Neurologic Complications of Varicella-Zoster Virus Reactivation: Clinical and Imaging Features
Varicella-zoster virus reactivation, especially in immunocompromised or elderly patients, can cause diverse neurologic complications detectable at MRI, making early recognition crucial for timely antiviral treatment and improved outcomes.
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (7) , e250084
Neurologic Complications of Varicella-Zoster Virus Reactivation: Clinical and Imaging Features
Varicella-zoster virus reactivation, especially in immunocompromised or elderly patients, can cause diverse neurologic complications detectable at MRI, making early recognition crucial for timely antiviral treatment and improved outcomes.
- 12 February 2026
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (5) , 1174-1178
Neuroimaging in Low- to Middle-Income Countries: A Health Equity Perspective
Inequities in neuroimaging access represent a major barrier to timely diagnosis and treatment of neurologic disease, particularly in low- and middle-income countries. This article examines factors contributing to neuroimaging access challenges in low- and middle-income countries and discusses practical, sustainable strategies to improve equity in global neuroimaging capacity. This State of Practice was developed by the members of the American Society of Neuroradiology's Diversity and Inclusion Committee, who reviewed published literature, global radiology workforce data, and Accreditation Council for Graduate Medical Education training statistics. The committee members also integrated insights from outreach experiences and collaborations with professional organizations working to improve global health. Bridging neuroimaging disparities requires coordinated action that integrates technological innovation, workforce development, and long-term collaboration. Expanding the use of portable and low-cost imaging systems, global teleradiology, and artificial intelligence alongside education, outreach, and policy engagement can help build capacity and improve access. Sustained partnerships between high- and low-resource regions are essential to achieving a more equitable and globally connected neuroradiology community with the potential to improve health outcomes worldwide.
- 12 February 2026
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (5) , 1174-1178
Neuroimaging in Low- to Middle-Income Countries: A Health Equity Perspective
Inequities in neuroimaging access represent a major barrier to timely diagnosis and treatment of neurologic disease, particularly in low- and middle-income countries. This article examines factors contributing to neuroimaging access challenges in low- and middle-income countries and discusses practical, sustainable strategies to improve equity in global neuroimaging capacity. This State of Practice was developed by the members of the American Society of Neuroradiology's Diversity and Inclusion Committee, who reviewed published literature, global radiology workforce data, and Accreditation Council for Graduate Medical Education training statistics. The committee members also integrated insights from outreach experiences and collaborations with professional organizations working to improve global health. Bridging neuroimaging disparities requires coordinated action that integrates technological innovation, workforce development, and long-term collaboration. Expanding the use of portable and low-cost imaging systems, global teleradiology, and artificial intelligence alongside education, outreach, and policy engagement can help build capacity and improve access. Sustained partnerships between high- and low-resource regions are essential to achieving a more equitable and globally connected neuroradiology community with the potential to improve health outcomes worldwide.
- 5 August 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (11) , 1325-1336
ACR Neck Imaging Reporting and Data System for MRI Version 2025
- 5 August 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (11) , 1325-1336
ACR Neck Imaging Reporting and Data System for MRI Version 2025
- Open Access
Mutational Profile of Blood and Tumor Tissue and Biomarkers of Response to PD-1 Inhibitors in Patients with Cutaneous Squamous Cell Carcinoma
Background/Objectives: Cutaneous squamous cell carcinoma (cSCC) harbors one of the most mutated genomes. There are limited data on the genomic profile and its predictive potential for response to immunotherapy with PD-1 inhibitors in cSCC. Methods: This study retrospectively reviewed cSCC patients treated with PD-1 inhibitor monotherapy at a single institution. Clinical characteristics, treatment outcomes, PD-L1 expression, tumor mutation burden (TMB), and genomic profile in tumor and blood were analyzed. Logistic regression and a support vector classifier were used to validate identified biomarkers of significance. Results: Twenty-five patients were evaluable for response and had genomics tested in tumor and/or blood. Of the total, 80% of patients achieved an objective response: 40% complete response (CR), 32% partial response (PR) for more than 6 months, and 8% stable disease (SD) for more than 1 year; 20% of patients progressed on treatment. With a median follow-up of 21 months, progression-free survival (PFS) was 28 months in responders vs. 3 months in non-responders (p = 0.00001). Median PD-L1 was 25% in responders vs. 10% in non-responders (p = 0.39). There was no difference in median TMB between responders and non-responders. Eight gene mutations were significantly more frequent in non-responders than in responders: CDK12 (p = 0.005), CTCF (p = 0.033), CTNNB1 (p = 0.033), IGF1R (p = 0.038), IKBKE (p = 0.016), MLH1 (0.033), QKI (p = 0.016), and TIPARP (p = 0.033). A support vector model of these genes classified responders and non-responders with an accuracy of 0.88 in the training data and 1.0 in the testing data. Conclusions: PD-1 inhibitor monotherapy produces an impressive response. Eight gene mutations were significantly more frequent in non-responders. PD-L1 and TMB were inconclusive in predicting treatment response to anti-PD-L1.
Open AccessMutational Profile of Blood and Tumor Tissue and Biomarkers of Response to PD-1 Inhibitors in Patients with Cutaneous Squamous Cell Carcinoma
Background/Objectives: Cutaneous squamous cell carcinoma (cSCC) harbors one of the most mutated genomes. There are limited data on the genomic profile and its predictive potential for response to immunotherapy with PD-1 inhibitors in cSCC. Methods: This study retrospectively reviewed cSCC patients treated with PD-1 inhibitor monotherapy at a single institution. Clinical characteristics, treatment outcomes, PD-L1 expression, tumor mutation burden (TMB), and genomic profile in tumor and blood were analyzed. Logistic regression and a support vector classifier were used to validate identified biomarkers of significance. Results: Twenty-five patients were evaluable for response and had genomics tested in tumor and/or blood. Of the total, 80% of patients achieved an objective response: 40% complete response (CR), 32% partial response (PR) for more than 6 months, and 8% stable disease (SD) for more than 1 year; 20% of patients progressed on treatment. With a median follow-up of 21 months, progression-free survival (PFS) was 28 months in responders vs. 3 months in non-responders (p = 0.00001). Median PD-L1 was 25% in responders vs. 10% in non-responders (p = 0.39). There was no difference in median TMB between responders and non-responders. Eight gene mutations were significantly more frequent in non-responders than in responders: CDK12 (p = 0.005), CTCF (p = 0.033), CTNNB1 (p = 0.033), IGF1R (p = 0.038), IKBKE (p = 0.016), MLH1 (0.033), QKI (p = 0.016), and TIPARP (p = 0.033). A support vector model of these genes classified responders and non-responders with an accuracy of 0.88 in the training data and 1.0 in the testing data. Conclusions: PD-1 inhibitor monotherapy produces an impressive response. Eight gene mutations were significantly more frequent in non-responders. PD-L1 and TMB were inconclusive in predicting treatment response to anti-PD-L1.
- 3 March 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (3) , 376-385
Potential Impact of Opportunistic CT for Closing Diagnosis Gaps in Primary Hyperparathyroidism
- 3 March 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (3) , 376-385
Potential Impact of Opportunistic CT for Closing Diagnosis Gaps in Primary Hyperparathyroidism
- 1 February 2025
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 224 (2) , e2432031
Opportunistic Assessment for Parathyroid Adenoma on CT: A Retrospective Cohort Study Evaluating Primary Hyperparathyroidism-Associated Morbidity Over 10 Years of Follow-Up
Background: Primary hyperparathyroidism (PHPT) is underdiagnosed. Opportunistic imaging-based parathyroid gland assessment is a proposed strategy for identifying patients at increased risk of undiagnosed PHPT. However, whether this approach is likely to identify individuals with clinically significant disease is unknown. Objective: This study's objective was to assess for associations of the presence of an enlarged parathyroid gland on contrast-enhanced CT with clinical outcomes causally related to PHPT. Methods: This retrospective cohort study included patients age 18 years old or older with at least one contrast-enhanced chest or neck CT performed from January 2012 to December 2012, at least one noncontrast CT covering the chest or neck region without date restriction, and at least one clinical encounter in the health system from January 2022 to December 2022. A neuroradiologist reviewed the CT examinations to determine the presence versus absence of an enlarged parathyroid gland on the 2012 study. Patient demographics, serum calcium results, and diagnosis codes for clinical outcomes causally related to PHPT were extracted from the EHR. Calcium results and diagnosis codes were classified as pre-existing if documented before, and as incident if documented after, the 2012 contrast-enhanced CT examination. Results: The cohort included 1198 patients (593 male; 605 female; mean age, 51.6 years), of whom 43 (3.6%) were assessed as having an enlarged parathyroid gland on the 2012 contrast-enhanced CT examination. PHPT was diagnosed in 16.3% of patients with, versus 0.3% of patients without, an enlarged parathyroid gland. After adjusting for age, sex, race, and ethnicity, presence of an enlarged parathyroid gland was associated with significantly increased odds of pre-existing nephrolithiasis (OR=2.71; p=.03), hypercalcemia (OR=5.30; p<.001), and PHPT (OR=12.59; p=.008) as well as increased odds of incident osteopenia or osteoporosis (OR=2.78; p=.008), nephrolithiasis (OR=4.95; p<.001), hypercalcemia (OR=7.58; p<.001), and PHPT (OR=148.01; p<.001). Conclusion: An enlarged parathyroid gland indicated increased PHPT risk as well as increased risk of pre-existing and incident clinical conditions causally related to PHPT. Clinical Impact: Opportunistic CT-based assessment is a promising strategy for identifying patients at increased risk of undiagnosed PHPT; such assessment could potentially prevent some PHPT-related complications through earlier diagnosis and treatment.
- 1 February 2025
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 224 (2) , e2432031
Opportunistic Assessment for Parathyroid Adenoma on CT: A Retrospective Cohort Study Evaluating Primary Hyperparathyroidism-Associated Morbidity Over 10 Years of Follow-Up
Background: Primary hyperparathyroidism (PHPT) is underdiagnosed. Opportunistic imaging-based parathyroid gland assessment is a proposed strategy for identifying patients at increased risk of undiagnosed PHPT. However, whether this approach is likely to identify individuals with clinically significant disease is unknown. Objective: This study's objective was to assess for associations of the presence of an enlarged parathyroid gland on contrast-enhanced CT with clinical outcomes causally related to PHPT. Methods: This retrospective cohort study included patients age 18 years old or older with at least one contrast-enhanced chest or neck CT performed from January 2012 to December 2012, at least one noncontrast CT covering the chest or neck region without date restriction, and at least one clinical encounter in the health system from January 2022 to December 2022. A neuroradiologist reviewed the CT examinations to determine the presence versus absence of an enlarged parathyroid gland on the 2012 study. Patient demographics, serum calcium results, and diagnosis codes for clinical outcomes causally related to PHPT were extracted from the EHR. Calcium results and diagnosis codes were classified as pre-existing if documented before, and as incident if documented after, the 2012 contrast-enhanced CT examination. Results: The cohort included 1198 patients (593 male; 605 female; mean age, 51.6 years), of whom 43 (3.6%) were assessed as having an enlarged parathyroid gland on the 2012 contrast-enhanced CT examination. PHPT was diagnosed in 16.3% of patients with, versus 0.3% of patients without, an enlarged parathyroid gland. After adjusting for age, sex, race, and ethnicity, presence of an enlarged parathyroid gland was associated with significantly increased odds of pre-existing nephrolithiasis (OR=2.71; p=.03), hypercalcemia (OR=5.30; p<.001), and PHPT (OR=12.59; p=.008) as well as increased odds of incident osteopenia or osteoporosis (OR=2.78; p=.008), nephrolithiasis (OR=4.95; p<.001), hypercalcemia (OR=7.58; p<.001), and PHPT (OR=148.01; p<.001). Conclusion: An enlarged parathyroid gland indicated increased PHPT risk as well as increased risk of pre-existing and incident clinical conditions causally related to PHPT. Clinical Impact: Opportunistic CT-based assessment is a promising strategy for identifying patients at increased risk of undiagnosed PHPT; such assessment could potentially prevent some PHPT-related complications through earlier diagnosis and treatment.
- 1 October 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (10) , e240018
Evaluation of Hearing Loss: Understanding Audiologic Testing to Refine Image Interpretation
The standard of reference for diagnosing and characterizing hearing loss is audiologic testing. The results of audiologic testing inform the imaging algorithm and the differential diagnosis for the underlying cause. Pure-tone audiometry tests the ability to hear tones across different frequencies, and the results are displayed as an audiogram. Tympanometry measures tympanic membrane compliance as a function of pressure to generate a tympanogram. Acoustic reflex testing helps differentiate third window lesions from other causes of conductive hearing loss. Clinical and audiologic assessment of sensorineural hearing loss helps in differentiating cochlear from retrocochlear causes. Symmetrical sensorineural hearing loss is typical of cochlear disease. Asymmetry increases the likelihood of a retrocochlear lesion, the most common of which among adults is vestibular schwannoma. Unlike patients with sensorineural hearing loss, who commonly have normal imaging studies, patients with conductive hearing loss are expected to have abnormal temporal bone CT studies. By incorporating the results of audiologic testing into their evaluation, radiologists can perform a more informed and more intentional search for the structural cause of hearing loss. The authors describe several audiogram configurations that suggest specific underlying mechanisms of conductive hearing loss. By providing a practical and accessible summary of the basics of audiologic testing, the authors empower the radiologist to leverage relevant clinical information and audiologic test results to interpret temporal bone imaging more confidently and more accurately, particularly temporal bone CT in the setting of conductive hearing loss. ©RSNA, 2024.
- 1 October 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (10) , e240018
Evaluation of Hearing Loss: Understanding Audiologic Testing to Refine Image Interpretation
The standard of reference for diagnosing and characterizing hearing loss is audiologic testing. The results of audiologic testing inform the imaging algorithm and the differential diagnosis for the underlying cause. Pure-tone audiometry tests the ability to hear tones across different frequencies, and the results are displayed as an audiogram. Tympanometry measures tympanic membrane compliance as a function of pressure to generate a tympanogram. Acoustic reflex testing helps differentiate third window lesions from other causes of conductive hearing loss. Clinical and audiologic assessment of sensorineural hearing loss helps in differentiating cochlear from retrocochlear causes. Symmetrical sensorineural hearing loss is typical of cochlear disease. Asymmetry increases the likelihood of a retrocochlear lesion, the most common of which among adults is vestibular schwannoma. Unlike patients with sensorineural hearing loss, who commonly have normal imaging studies, patients with conductive hearing loss are expected to have abnormal temporal bone CT studies. By incorporating the results of audiologic testing into their evaluation, radiologists can perform a more informed and more intentional search for the structural cause of hearing loss. The authors describe several audiogram configurations that suggest specific underlying mechanisms of conductive hearing loss. By providing a practical and accessible summary of the basics of audiologic testing, the authors empower the radiologist to leverage relevant clinical information and audiologic test results to interpret temporal bone imaging more confidently and more accurately, particularly temporal bone CT in the setting of conductive hearing loss. ©RSNA, 2024.
- 6 September 2024
- Published by SAGE Publications in The American Surgeon™
- Vol. 91 (2) , 178-185
Body Composition in Primary Hyperparathyroidism: A Potential Contributor to Weakness and Fatigue
Background: Primary hyperparathyroidism (PHPT) patients commonly report weakness and fatigue, though the underlying mechanisms are uncertain. Our purpose is to determine whether CT-derived muscle and adipose tissue metrics are associated with weakness and fatigue in PHPT patients. Methods: For this retrospective study, cross-sectional muscle and adipose tissue metrics were derived from CTs in PHPT patients undergoing preoperative imaging within 1 year of parathyroid surgery. Skeletal muscle index (SMI) and visceral adipose tissue (VAT)/subcutaneous adipose tissue (SAT) ratio were calculated based on a single CT image at the level of the L3 vertebra. Established sex-specific SMI thresholds were used to define sarcopenia. Demographic and clinical data were collected from the electronic health record. When available, postoperative CT images were analyzed to assess for changes in body composition pre- and post-parathyroidectomy. Results: The cohort comprised 53 PHPT patients (38 females, 15 males, mean age 61.4 years), of whom 24 (45%) reported weakness, 43 (81%) reported fatigue, and 31 (58%) met CT-based criteria for sarcopenia. Lower SMI was significantly associated with preoperative weakness in females but not males. For both weakness and fatigue, VAT/SAT ratios were higher in symptomatic females and lower in symptomatic males than their asymptomatic counterparts, though these differences were not statistically significant. In patients with postoperative CTs (n = 23), no significant changes in CT metrics were observed after parathyroidectomy. Discussion: In females but not males with PHPT, subjective preoperative weakness was significantly associated with lower SMI. Effects of parathyroid hormone on skeletal muscle and visceral adiposity may differ by sex.
- 6 September 2024
- Published by SAGE Publications in The American Surgeon™
- Vol. 91 (2) , 178-185
Body Composition in Primary Hyperparathyroidism: A Potential Contributor to Weakness and Fatigue
Background: Primary hyperparathyroidism (PHPT) patients commonly report weakness and fatigue, though the underlying mechanisms are uncertain. Our purpose is to determine whether CT-derived muscle and adipose tissue metrics are associated with weakness and fatigue in PHPT patients. Methods: For this retrospective study, cross-sectional muscle and adipose tissue metrics were derived from CTs in PHPT patients undergoing preoperative imaging within 1 year of parathyroid surgery. Skeletal muscle index (SMI) and visceral adipose tissue (VAT)/subcutaneous adipose tissue (SAT) ratio were calculated based on a single CT image at the level of the L3 vertebra. Established sex-specific SMI thresholds were used to define sarcopenia. Demographic and clinical data were collected from the electronic health record. When available, postoperative CT images were analyzed to assess for changes in body composition pre- and post-parathyroidectomy. Results: The cohort comprised 53 PHPT patients (38 females, 15 males, mean age 61.4 years), of whom 24 (45%) reported weakness, 43 (81%) reported fatigue, and 31 (58%) met CT-based criteria for sarcopenia. Lower SMI was significantly associated with preoperative weakness in females but not males. For both weakness and fatigue, VAT/SAT ratios were higher in symptomatic females and lower in symptomatic males than their asymptomatic counterparts, though these differences were not statistically significant. In patients with postoperative CTs (n = 23), no significant changes in CT metrics were observed after parathyroidectomy. Discussion: In females but not males with PHPT, subjective preoperative weakness was significantly associated with lower SMI. Effects of parathyroid hormone on skeletal muscle and visceral adiposity may differ by sex.
- Open Access
Radiographic Response Assessments and Standardized Imaging Interpretation Criteria in Head and Neck Cancer on FDG PET/CT: A Narrative Review
Introduction: There is growing interest in the development and application of standardized imaging criteria (SIC), to minimize variability and improve the reproducibility of image interpretation in head and neck squamous cell carcinoma (HNSCC). Methods: “Squamous cell carcinoma” AND “standardized interpretation criteria” OR “radiographic response assessment” were searched using PubMed and Google Scholar for articles published between 2009 and 2024, returning 56 publications. After abstract review, 18 were selected for further evaluation, and 6 different SICs (i.e., PERCIST, Porceddu, Hopkins, NI-RADS, modified Deauville, and Cuneo) were included in this review. Each SIC is evaluated in the context of 8 desired traits of a standardized reporting system. Results: Two SICs have societal endorsements (i.e., PERCIST, NI-RADS); four can be used in the evaluation of locoregional and systemic disease (i.e., PERCIST, Hopkins, NI-RADS, Cuneo), and four have specific categories for equivocal imaging results (i.e., Porceddu, NI-RADS, modified Deauville, and Cuneo). All demonstrated areas for future improvement in the context of the 8 desired traits. Conclusion: Multiple SICs have been developed for and demonstrated value in HNSCC post-treatment imaging; however, these systems remain underutilized. Selecting an SIC with features that best match the needs of one’s practice is expected to maximize the likelihood of successful implementation.
Open AccessRadiographic Response Assessments and Standardized Imaging Interpretation Criteria in Head and Neck Cancer on FDG PET/CT: A Narrative Review
Introduction: There is growing interest in the development and application of standardized imaging criteria (SIC), to minimize variability and improve the reproducibility of image interpretation in head and neck squamous cell carcinoma (HNSCC). Methods: “Squamous cell carcinoma” AND “standardized interpretation criteria” OR “radiographic response assessment” were searched using PubMed and Google Scholar for articles published between 2009 and 2024, returning 56 publications. After abstract review, 18 were selected for further evaluation, and 6 different SICs (i.e., PERCIST, Porceddu, Hopkins, NI-RADS, modified Deauville, and Cuneo) were included in this review. Each SIC is evaluated in the context of 8 desired traits of a standardized reporting system. Results: Two SICs have societal endorsements (i.e., PERCIST, NI-RADS); four can be used in the evaluation of locoregional and systemic disease (i.e., PERCIST, Hopkins, NI-RADS, Cuneo), and four have specific categories for equivocal imaging results (i.e., Porceddu, NI-RADS, modified Deauville, and Cuneo). All demonstrated areas for future improvement in the context of the 8 desired traits. Conclusion: Multiple SICs have been developed for and demonstrated value in HNSCC post-treatment imaging; however, these systems remain underutilized. Selecting an SIC with features that best match the needs of one’s practice is expected to maximize the likelihood of successful implementation.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (8) , e240129
RadioGraphics Update: Parathyroid CT and Primary Hyperparathyroidism
Editor's Note.-RadioGraphics Update articles supplement or update information found in full-length articles previously published in RadioGraphics. These updates, written by at least one author of the previous article, provide a brief synopsis that emphasizes important new information such as technological advances, revised imaging protocols, new clinical guidelines involving imaging, or updated classification schemes.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (8) , e240129
RadioGraphics Update: Parathyroid CT and Primary Hyperparathyroidism
Editor's Note.-RadioGraphics Update articles supplement or update information found in full-length articles previously published in RadioGraphics. These updates, written by at least one author of the previous article, provide a brief synopsis that emphasizes important new information such as technological advances, revised imaging protocols, new clinical guidelines involving imaging, or updated classification schemes.